Buy Rating for Plus Therapeutics: Strategic Advancements and Promising Developments in CNSide Diagnostics and LM Program
I'm PortAI, I can summarize articles.
Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Plus Therapeutics with a $3.00 price target, citing strategic advancements in CNSide diagnostics and the LM program. The company has expanded CNSide diagnostics to 48 states, secured insurance coverage for 67 million lives, and is advancing its LM treatment pipeline. H.C. Wainwright also reiterated a Buy rating with a $2.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments